We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$990M
AUM Growth
-$95.1M
Cap. Flow
-$12.4M
Cap. Flow %
-1.25%
Top 10 Hldgs %
70.6%
Holding
53
New
12
Increased
7
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$58.8M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$42.9M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$34.9M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$26.8M
5
CYCN icon
Cyclerion Therapeutics
CYCN
+$11M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$42.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.3M
3
ARGX icon
argenx
ARGX
+$31M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$24.9M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
26
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.52M 0.66%
2,312,688
+49,200
+2% +$196K
MRSN
27
DELISTED
Mersana Therapeutics
MRSN
$5.64M 0.57%
55,689
-36,311
-39% -$4.28M
CRIS icon
28
Curis
CRIS
$3.61M
$5.55M 0.56%
7,456
– –
NGNE icon
29
Neurogene
NGNE
$732M
$5.35M 0.54%
113,294
– –
RYTM icon
30
Rhythm Pharmaceuticals
RYTM
$7.38B
$4.91M 0.5%
223,167
-177,671
-44% -$4.49M
SLDB icon
31
Solid Biosciences
SLDB
$1.05B
$4.75M 0.48%
+55,133
New +$6.01M
NGM
32
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.64M 0.47%
+316,900
New +$4.64M
KZR
33
DELISTED
Kezar Life Sciences
KZR
$4.5M 0.45%
58,329
-27,318
-32% -$4.25M
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.71M 0.27%
352,284
-35,594
-9% -$542K
VCEL icon
35
Vericel Corp
VCEL
$2.1B
$2.48M 0.25%
131,001
– –
SYRS
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.3M 0.23%
+24,848
New +$1.73M
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$1.39M 0.14%
+111,111
New +$1.28M
GMDA
38
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$265K 0.03%
+52,120
New +$409K
TCRR
39
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$231K 0.02%
+16,114
New +$257K
ABUS icon
40
Arbutus Biopharma
ABUS
$1B
– –
-2,172,883
Closed -$7.78M
ARVN icon
41
Arvinas
ARVN
$600M
– –
-50,000
Closed -$738K
ASMB icon
42
Assembly Biosciences
ASMB
$694M
– –
-96,133
Closed -$18.3M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.3B
– –
-360,819
Closed -$42.5M
ASND icon
44
PUT
Ascendis Pharma A/S
ASND
$16.3B
– –
-360,000
Closed -$42.4M
DNTH icon
45
Dianthus Therapeutics
DNTH
$5.92B
– –
-79,862
Closed -$21M
KYNB
46
PUT
Kyntra Bio
KYNB
$32.5M
– –
-40,000
Closed -$54.4M
IRWD icon
47
CALL
Ironwood Pharmaceuticals
IRWD
$682M
– –
-1,295,012
Closed -$14.7M
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$424M
– –
-450,000
Closed -$7.89M
SRRK icon
49
Scholar Rock
SRRK
$7.04B
– –
-338,668
Closed -$6.36M
ZLAB icon
50
Zai Lab
ZLAB
$2.93B
– –
-78,519
Closed -$2.32M
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2019 Portfolio in Review

As of Q2 2019, EcoR1 Capital held 53 positions worth $990M, down 8.8% from $1.08B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

EcoR1 Capital's Q2 2019 filing shows 12 new, 7 increased, 12 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M. The largest sale was Ascendis Pharma A/S, an estimated $42.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2019 buy was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2019, an estimated $58.8M increase.
  • EcoR1 Capital's biggest Q2 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $31.3M.
  • EcoR1 Capital fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $42.5M.
  • EcoR1 Capital's ten largest holdings make up 71% of its $990M portfolio in Q2 2019.
  • EcoR1 Capital opened 12 new positions and closed 14 in Q2 2019.
  • EcoR1 Capital's portfolio value fell 8.8% quarter-over-quarter to $990M.

Based on EcoR1 Capital's 13F filing for Q2 2019, filed 14 Aug 2019.